EGFR and non-small cell lung carcinoma: Here, we introduce a novel panel of NSCLC cell lines consisting of the EGFR‐mutant cell lines HCC827 and HCC4006 and their sublines adapted to the EGFR tyrosine kinase inhibitors gefitinib (HCC827rGEFI2μm, HCC4006rGEFI1μm), erlotinib (HCC827rERLO2μm, HCC4006rERLO1μm) and afatinib (HCC827rAFA50nm, HCC4006rAFA100nm).